Clinical Trial Update: Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating preemptive therapy with CMV-specific T cell infusions to prevent refractory CMV infection after transplantation has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cmv Infection

Drugs mentioned

• CMV-specific T cell infusion

Snippet

Sponsor: Peking University People's Hospital | Conditions: CMV Infection | Phase 1, Phase 2 | Status: COMPLETED